Lack of enhancing effects of degraded lambda-carrageenan on the development of beta-catenin-accumulated crypts in male DBA/2J mice initiated with azoxymethane.
Effect of degraded lambda-carrageenan, which induces colitis in rodents, on the development of beta-catenin-accumulated crypts (BCAC) being putative precancer lesions of colon cancer was investigated in male DBA/2J mice initiated with azoxymethane (AOM). In a preliminary experiment, male DBA/2J mice among seven different strains (A/J, BALB/c, C3H/HeN, C57BL/6J, CBA/N, DBA/1J, and DBA/2J) of male mice were most sensitive to degraded lambda-carrageenan. Therefore, male DBA/2J mice were intraperitonially injected AOM (10 mg/kg body weight), and then 2% degraded lambda-carrageenan in drinking water for one or two weeks, starting one week after dosing of AOM. Thereafter animals were no further treated up to week 26. At week 26, the frequency of BCAC in the colonic mucosa was 12.50+/-2.46 in the AOM alone group, 11.30+/-3.50 in the AOM/degraded lambda-carrageenan (for one week) group, and 11.60+/-2.27 in the AOM/degraded lambda-carrageenan (for two weeks) group. The findings suggest that degraded lambda-carrageenan treatment for one or two weeks did not affect the occurrence of BCAC. Our results may indicate no enhancing or promoting effects of degraded lambda-carrageenan on colon carcinogenesis in mice initiated with AOM.
Hata
Kazuya
K
BMR Laboratories, Sunplanet Co., Ltd, 4388 Hagiwara, Kamiishidu, Yoro-gun, Gifu 503-1602, Japan.
Tanaka
Takuji
T
Kohno
Hiroyuki
H
Suzuki
Rikako
R
Qiang
Sheng Hong
SH
Kuno
Toshiya
T
Hirose
Yoshinobu
Y
Hara
Akira
A
Mori
Hideki
H
D000818:Animals; D001397:Azoxymethane / Q000633:toxicity*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000096:biosynthesis; D002273:Carcinogens / Q000633:toxicity*; D002351:Carrageenan / Q000737:chemistry / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D008815:Mice, Inbred Strains; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000473:pathology; D013045:Species Specificity; D051176:beta Catenin / Q000032:analysis / Q000096:biosynthesis*
D014408:Biomarkers, Tumor; D002273:Carcinogens; D051176:beta Catenin; D002351:Carrageenan; D001397:Azoxymethane